What were the key takeaways from Ionis Pharmaceuticals’s earnings call?

What guidance did Ionis Pharmaceuticals's management provide for the next earnings period?

What does Ionis Pharmaceuticals do and what are its main business segments?

Did Ionis Pharmaceuticals beat or miss consensus estimates last quarter?

What factors drove the changes in Ionis Pharmaceuticals's revenue and profit?

What is Ionis Pharmaceuticals's gross profit margin?

What is Ionis Pharmaceuticals's latest dividend and current dividend yield?

What were the key takeaways from Ionis Pharmaceuticals's earnings call?

- **Revenue Growth**: 34% YoY to $944M, driven by commercial ($436M) and R&D ($508M). 
- **Key Launches**: TRYNGOLZA ($108M), DAWNZERA ($8M), and sHTG pipeline ($2B+ peak). 
- **Pipeline Momentum**: 5 late-stage partner readouts (Bepirovirsen, pelacarsen), 3 independent launches (sHTG, Zilganersen, Angelman). 
- **Financial Discipline**: 2026 guidance: $800-825M revenue, $500-550M non-GAAP loss. 
- **Strategic Wins**: FDA Breakthrough for olezarsen, 200+ field team expansion, $1.6B cash for growth.

**【CEO Summary Section】**
- 2025 was a transformative year with two independent launches: TRYNGOLZA (FCS) and DAWNZERA (HAE), generating $944 million in revenue (34% YoY growth). 
- Olezarsen for severe hypertriglyceridemia (sHTG) achieved Phase III success, with FDA submission and potential $2+ billion peak sales. 
- Zilganersen for Alexander disease submitted NDA, targeting first neurology launch in H2 2026. 
- Partnered pipeline includes Bepirovirsen (HBV) with GSK, and pelacarsen (Lp(a)) Phase III readout mid-2026. 
- On track for cash flow breakeven by 2028 with disciplined spending and expanding commercial portfolio.

**【CFO Financial Commentary】**
- 2025 Revenue: $944M (34% YoY growth), split 46% commercial ($436M) and 54% R&D ($508M). 
- TRYNGOLZA sales: $108M (Q4: $50M, +56% QoQ), DAWNZERA: $8M. 
- Royalties: $285M (+11% YoY), driven by SPINRAZA and WAINUA. 
- 2026 Guidance: $800-825M revenue (20% YoY growth), non-GAAP loss $500-550M. 
- Cash position: $1.6B, supporting sHTG launch and pipeline advancement.

**【Commercial Execution Highlights】**
- TRYNGOLZA: 75% prescriptions from specialists, 100% patient conversion from free trial. 
- DAWNZERA: Strong early adoption, 100% conversion from trial to paid therapy. 
- Olezarsen: 200+ field team hired, $2B+ peak sales confidence. 
- Zilganersen: 300+ U.S. patients with Alexander disease, H2 2026 launch prep underway.

**【Pipeline & Strategic Initiatives】**
- sHTG: Phase III data shows 72% triglyceride reduction, 85% AP attack reduction. 
- Angelman Syndrome: Breakthrough Therapy Designation, Phase III REVEAL study enrolling. 
- Next-gen Lp(a) siRNA (ION775): 6-month dosing potential, IND in 2026. 
- APOL1 partnership with AstraZeneca: Phase II expected, targeting kidney disease.


Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: Q3 revenue up 17% YoY to $157M, driven by TRYNGOLZA ($32M Q3 sales) and DAWNZERA launches. 2025 guidance raised to $875-900M.
- **Pipeline Milestones**: Olezarsen shows 85% AP reduction in sHTG; zilganersen stabilizes Alexander disease gait speed. Both targeting 2026 launches.
- **Strategic Growth**: >$1B peak sales expected for olezarsen; DAWNZERA >$500M. 4 partnered launches by 2027, with $2.1B+ cash for execution.

**【CEO Summary Section】**
- **Strong Launch Momentum**: TRYNGOLZA achieved $32M in Q3 sales, up 70% QoQ, with 70% prescribers from cardiologists and endocrinologists. DAWNZERA secured first prescriptions within 10 days of approval, with early adoption from HAE patients.
- **Pipeline Breakthroughs**: Olezarsen reduced triglycerides by 72% in sHTG and acute pancreatitis events by 85%, while zilganersen showed disease-modifying effects in Alexander disease. Both programs target 2026 launches.
- **Partnership Growth**: 4 partnered pipeline launches expected by 2027, targeting rare and prevalent diseases, with Sobi initiating European TRYNGOLZA rollout.

**【CFO Financial Commentary】**
- **Revenue Growth**: Q3 revenue $157M (+17% YoY), 9M total $740M (+55% YoY). TRYNGOLZA sales guidance raised to $85-95M for 2025. Non-GAAP operating loss $275-300M, with $2.1B+ cash balance.
- **Cost Management**: Year-to-date non-GAAP expenses up 9%, driven by U.S. launch investments. R&D expenses down YoY, with 23% of R&D funding late-stage programs.

**【Q&A Highlights】**
- **Olezarsen Launch Strategy**: Targeting 20,000 HCPs in sHTG, with 360,000 high-risk patients. Expected peak sales >$1B, driven by 85% AP reduction and triglyceride lowering. Pricing decisions pending AHA data (Nov 8).
- **DAWNZERA Market Potential**: >$500M peak sales in HAE, with 7,000 U.S. patients, 75% on prophylaxis. Early adoption from switch and treatment-naive patients.
- **Pipeline Investment**: $2.1B+ cash balance supports 2026 launches of olezarsen and zilganersen, with disciplined capital allocation prioritizing internal growth.

Ionis Pharmaceuticals, Inc. (IONS) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: Q2 revenue $452M (+100% YoY), 2025 guidance raised to $850M. Tryngolza sales $19M (Q2) vs. $6M (Q1).
- **Pipeline Breakthroughs**: Donidalorsen HAE launch on track (August 21), Olezarsen sHTG Phase III data in Q3. Zilganersen Alexander's disease readout Q4.
- **Commercial Excellence**: 90% patient OOP coverage, 3,000+ HCP engagements, 60% commercial payer mix for Tryngolza.
- **Financial Strength**: $2B cash balance, 70% YoY revenue growth, operating loss narrowing to $300-325M.

**【CEO Summary Section】**
- **Strong Q2 Performance**: Revenue of $452 million (2x YoY), driven by Tryngolza's $19 million net sales (3x Q1). Updated 2025 guidance: $850 million revenue, up $100 million from prior.
- **Pipeline Momentum**: 2025 launches include Donidalorsen (HAE) and Olezarsen (sHTG). Phase III data expected for Zilganersen (Alexander's disease) and Olezarsen (sHTG) in Q3.
- **Commercial Success**: Tryngolza's 90% patient OOP coverage, 3,000+ HCP engagements, and 60% commercial payer mix highlight execution strength.

**【CFO Financial Commentary】**
- **Q2 Financials**: Non-GAAP net income $154 million; 70% YoY first-half revenue growth to $584 million. Operating expenses +8% YoY, with 2/3 of R&D funding late-stage programs.
- **Guidance Update**: 2025 revenue $850M (vs. $750M prior), operating loss $300-325M, cash balance $2B. Tryngolza 2025 sales $75-80M, Donidalorsen modest 2025 contribution.

**【Q&A Highlights】**
- **Tryngolza Growth**: Sequential Q3/Q4 growth driven by FCS patient identification; 3,000+ potential U.S. patients. Q2 sales $19M, Q1 $6M.
- **sHTG Data Expectations**: Olezarsen targeting 50-60% triglyceride reduction vs. SoC. CORE/CORE2 AP events exceed FCS BALANCE (13 events), supporting trend analysis.
- **Donidalorsen Launch**: FDA PDUFA August 21; 20,000+ U.S. HAE patients, 20% annual therapy switch rate. Switch study shows 62% attack reduction, 84% patient preference.
- **Pricing Strategy**: sHTG pricing TBD post-data; focus on sHTG as 1M+ U.S. patients with high-risk triglycerides.

Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript

- **Revenue Beat**: Q1 $132M (+10% YoY), driven by $6M+ TRYNGOLZA sales and licensing deals. 2025 guidance raised to $725-750M.
- **Pipeline Momentum**: 4 late-stage programs (sHTG, Alexander's, sapablursen, Angelman) with multibillion-dollar potential.
- **Commercial Success**: TRYNGOLZA 90%+ patient zero copay, donidalorsen 84% patient preference in SWITCH study.
- **Financial Strength**: $1.9B cash, operating loss reduced to <$375M, +25% cost efficiency.

**【CEO Opening Remarks】**
- **Strategic Focus**: Emphasized execution on strategic priorities amid FDA and tariff policy uncertainties. Highlighted successful licensing deals driving 2025 financial guidance upgrade.
- **Product Launch Momentum**: TRYNGOLZA (FCS) exceeded Q1 expectations with $6M+ sales, targeting 3,000+ U.S. patients. Donidalorsen (HAE) on track for Q3 launch with potential $500M+ peak sales.
- **Pipeline Expansion**: 4 late-stage programs (olezarsen sHTG, zilganersen Alexander's disease, sapablursen, ION582) poised for 2025-2026 data reads, representing multibillion-dollar revenue potential.

**【CFO Financial Update】**
- **Q1 2025 Results**: Revenue $132M (+10% YoY), with $6M+ product sales from TRYNGOLZA. SPINRAZA royalties $48M (+25% YoY), WAINUA royalties $9M.
- **Guidance Upgrade**: 2025 revenue raised to $725-750M (+20% YoY), driven by sapablursen licensing ($280M upfront) and growing commercial portfolio. Operating loss reduced to <$375M, cash position $1.9B.
- **Cost Efficiency**: Non-GAAP expenses +<5% YoY, disciplined R&D allocation to late-stage programs.

**【Commercial Highlights】**
- **TRYNGOLZA Execution**: 90%+ patient zero copay, 50% cardiologist prescribers, favorable payer access. Focused on new patient identification and HCP education.
- **Olezarsen Progress**: Phase III data expected Q3, targeting 1M+ sHTG patients. ESSENCE safety study data Q2, sNDA submission Q4 if positive.
- **Donidalorsen Prep**: Field team 90%+ hired, HAE market 20,000+ U.S. patients with 20% annual therapy switching rate. SWITCH study shows 84% patient preference over prior treatments.

**【Q&A Key Takeaways】**
- **FDA & Tariff Impact**: No delays in donidalorsen PDUFA (August 21) or clinical trials. Manufacturing supply chain diversified (U.S., Europe, South Korea), no material tariff impact to date.
- **sHTG AP Risk Reduction**: CORE/CORE2 trials not powered for AP, but 22%/13% baseline AP history in cohorts. Combining datasets for secondary analysis, targeting triglyceride reduction as primary endpoint.
- **WAINUA Growth**: Medicare Part D redesign expected to increase patient access and adherence. AstraZeneca reports strong U.S. demand, EU approval expansion.
- **Angelman Syndrome**: Phase III start Q2, enrollment on track for 2026 completion, leveraging FDA-aligned trial design.


Ionis Pharmaceuticals (IONS)-30 Apr 25-2025 Q1 Earnings call transcript

- **Breakthrough Launch**: TRYNGOLZA achieved first patient treatment in 2 weeks post-FDA approval, with early momentum in FCS and sHTG markets.
- **$5B+ Revenue Vision**: Ionis targets $3B from owned medicines (olezarsen, ION582) and $2B in royalties, driven by 7 Phase III readouts by 2026.
- **2025 Financial Confidence**: >$600M revenue, <4.95 billion operating loss, and $1.7B cash, supported by WAINUA growth (84% Q4 sales growth) and new launches.
- **Clinical Excellence**: sHTG Phase III powered for triglyceride reduction, with potential AP event reduction; Angelman Phase III enrollment on track with 2 dose levels.

**【CEO Summary Section】**
- Launched TRYNGOLZA for FCS in Q4 2024, achieving first patient treatment within 2 weeks of FDA approval.
- Projected 3 additional independent launches over the next 3 years: donidalorsen (HAE, Q3 2025), sHTG indication for olezarsen (2025), and zilganersen (Alexander disease, 2026).
- 4 partnered launches expected over the next 3 years, including pelacarsen (Lp(a) CVD), eplontersen (ATTR-CM), bepirovirsen (HBV), and sefaxersen (IgAN).
- Total peak revenue potential exceeds $5 billion, driven by $3 billion from Ionis-owned medicines and $2 billion in royalties from partnered programs.

**【CFO Financial Commentary】**
- 2024 non-GAAP operating loss: $345 million (vs. $495 million guidance), with revenue of $705 million (+$130M over guidance).
- Key revenue sources: SPINRAZA royalties ($216M), WAINUA product sales ($85M), and early TRYNGOLZA contributions.
- 2025 guidance: >$600M revenue, <4.95 billion in non-GAAP operating loss, and $1.7 billion cash by year-end.
- Revenue growth driven by commercial expansion (TRYNGOLZA, donidalorsen) and partnered programs (WAINUA, SPINRAZA).

**【Q&A Highlights】**
- **sHTG Launch Dynamics**: Phase III data expected H2 2025, with sNDA submission planned post-CORE/CORE2 results. Focus on 500+ mg/dL triglyceride population with high unmet need.
- **WAINUA Growth**: Q4 2024 sales up 84% QoQ, 40% new-to-brand share, and >80% patients paying $0 out-of-pocket.
- **Partnership Strategy**: Securing OUS partners for FCS/sHTG, while retaining global rights for alpha-synuclein (MSA) and LRRK2 (PD) programs.
- **Angelman Enrollment**: Phase III initiation H1 2025, targeting 300+ patients with 2 dose levels powered against placebo.

**【Operational Milestones】**
- HAE launch prep: hired donidalorsen VP of Sales, with field teams to be finalized pre-August 2025 PDUFA date.
- sHTG commercial readiness: scaling Ionis Every Step program for broader patient engagement.
- Pipeline advancement: 7 Phase III readouts by end-2026, including zilganersen (Alexander disease) and ION582 (Angelman syndrome).

Actual												-0.35	-0.23	-0.22	-2.44	-0.64	-0.57	-0.58	1.41	-0.46	-0.74	-0.33	-0.37	-0.87	-0.6	-1.03	-0.06	-0.98	-0.45	-0.95	-0.66	-0.93	0.7	-0.8	-1.41
Forecast												-0.1355	-0.2585	-0.1297	0.2588	-0.5085	-0.5548	-0.4875	-0.0437	-0.6872	-0.6101	-0.7233	-0.9399	-0.8702	-0.883	-1.0083	-0.8005	-1.0475	-0.9366	-1.1374	-1.1241	-1.0978	-0.0911	-1.2182	-1.3135
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-158.30%	+11.03%	-69.62%	-1042.81%	-25.86%	-2.74%	-18.97%	+3326.54%	+33.06%	-21.29%	+54.38%	+60.63%	+0.02%	+32.05%	-2.15%	+92.50%	+6.44%	+51.95%	+16.48%	+41.29%	+15.29%	+868.39%	+34.33%	-7.35%

IONS

IONS fundamentals

IONS Q4 2025 Earnings

Earnings Call

You can ask Aime

IONS

IONS fundamentals

IONS Q4 2025 Earnings

Earnings Call

IONS Earnings Call Summary for Q4/20258:30 AM on Feb 25, 2026

IONS Earnings Call Summary for Q3/202511:30 AM on Oct 29, 2025

IONS Earnings Call Summary for Q2/202511:30 AM on Jul 30, 2025

IONS Earnings Call Summary for Q1/202511:30 AM on Apr 30, 2025

IONS Earnings Call Summary for Q4/202411:30 AM on Feb 19, 2025

You can ask Aime